Literature DB >> 10671660

Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions.

H Cardenes1, M E Randall.   

Abstract

Although important advances in surgery, chemotherapy (CT), and radiation therapy (RT) have been made, overall survival for patients with ovarian cancer (OC) has not changed significantly. Despite its long history in the treatment of OC and its proven curative role in patients with microscopic or minimal residual disease, the proper role of RT in the management of OC is not clearly established. Although the use of primary adjuvant RT (whole abdominal irradiation) has declined in the last 15 years, there has been a resurgence of interest in RT as part of a combined modality approach and as salvage therapy for patients with small-volume persistent disease after primary cytoreductive surgery and platinum-based CT. This article reviews the evidence supporting the use of RT alone or combined with chemotherapy as primary adjuvant therapy or in the salvage setting. Current issues in the radiotherapeutic management are discussed along with ideas for future clinical research directions.

Entities:  

Mesh:

Year:  2000        PMID: 10671660     DOI: 10.1016/s1053-4296(00)80022-3

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  6 in total

Review 1.  Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.

Authors:  José A García-Sáenz; Ana Custodio; Antonio Casado; José Antonio Vidart; Pluvio J Coronado; Miguel Martín; Sara López-Tarruella; Javier Puente; Cristina Fernández; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

2.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Authors:  Beverly A Teicher; Krishna Menon; Enrique Alvarez; Chuan Shih; Margaret M Faul
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

3.  Treatment-interval associated effect of irradiation on locoregionally-relapsed ovarian cancer.

Authors:  Motoaki Saito; Chihiro Kanehira; Seiji Isonishi
Journal:  Mol Clin Oncol       Date:  2014-06-16

4.  Involved-field radiation therapy for locoregionally recurrent ovarian cancer.

Authors:  Aaron P Brown; Anuja Jhingran; Ann H Klopp; Kathleen M Schmeler; Pedro T Ramirez; Patricia J Eifel
Journal:  Gynecol Oncol       Date:  2013-05-04       Impact factor: 5.482

5.  Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy.

Authors:  Jee Suk Chang; Woong Sub Koom; Sang Wun Kim; Sunghoon Kim; Yong Bae Kim; Young Tae Kim; Gwi Eon Kim
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

6.  Involved-field radiation therapy for selected cases of recurrent ovarian cancer.

Authors:  Nalee Kim; Jee Suk Chang; Sang Wun Kim; Gun Min Kim; Jung Yun Lee; Yong Bae Kim
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.